Neratinib

Puma Biotechnology will host a conference call on November 7, 2024, following Q3 2024 financial results release. The call will be accessible via phone or webcast on Puma's website, with a replay available for 90 days. Puma is a biopharmaceutical company focusing on cancer care, with products like NERLYNX® and alisertib in development.

Zacks Research raised Puma Biotechnology's FY2026 EPS estimate to $0.72 from $0.69. StockNews.com downgraded PBYI from 'strong-buy' to 'buy'. PBYI opened at $2.88 with a market cap of $138.93M. The company reported a quarterly EPS of ($0.09), beating estimates by $0.01. Director Michael Patrick Miller sold 23,358 shares at $3.49 each. Institutional investors own 61.29% of PBYI.

Zacks Research lowered Puma Biotechnology's FY2025 earnings estimate to $0.19/share from $0.22. StockNews.com downgraded PBYI from "strong-buy" to "buy". PBYI traded up 0.8% at $2.58, with a market cap of $126.55M. Insiders sold 82,263 shares over the last 3 months. Institutional investors own 61.29% of PBYI.

American Century Companies Inc. increased its stake in Puma Biotechnology by 98.5% in Q2, owning 738,902 shares worth $2,409,000. Other investors also adjusted their holdings, with institutional investors owning 61.29% of the company's stock. Puma Biotechnology's stock opened at $2.58 on Friday, with a market cap of $126.55 million. The company reported a net margin of 4.01% and a return on equity of 18.36% in Q2, beating consensus estimates. Insiders sold 82,263 shares valued at $286,469 over the last quarter, while corporate insiders own 23.70% of the stock. Analysts have varied opinions on PBYI shares, with some downgrading the rating.

Bank of New York Mellon Corp increased its stake in Puma Biotechnology by 63.6% in Q2, owning 308,997 shares worth $1,007,000. Other investors also adjusted their holdings, with Lazard Asset Management LLC raising its stake by 5,129.0% and Jump Financial LLC by 131.7%. Puma Biotechnology reported $47.10 million in revenue for Q2, surpassing estimates, and insiders sold 82,263 shares in the last three months. StockNews.com downgraded Puma Biotechnology from a "strong-buy" to a "buy" rating.